Bertil Olofsson
Publications by Year
Research Areas
Heart Failure Treatment and Management, Blood Pressure and Hypertension Studies, Cardiovascular Function and Risk Factors, Cardiac pacing and defibrillation studies, Analytical Methods in Pharmaceuticals
Most-Cited Works
- → Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial(2003)2,956 cited
- → Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial(2003)2,608 cited
- → Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme(2003)1,881 cited
- → Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial(2003)1,670 cited
- → The Study on Cognition and Prognosis in the Elderly (SCOPE)(2003)1,408 cited
- CHARM IN-VESTIGATORS AND COMMITTEES. EFFECTS OF CANDESARTAN IN PATIENTS WITH CHRONIC HEART FAILURE AND REDUCED LEFT-VENTRICULAR SYSTOLIC FUNCTION TAKING ANGIOTENSIN-CONVERTING-ENZYME INHIBITORS: THE CHARM-ADDED TRIAL(2003)
- → Adherence to candesartan and placebo and outcomes in chronic heart failure in the CHARM programme: double-blind, randomised, controlled clinical trial(2005)480 cited
- CHARM INVESTIGATORS AND COMMITTEES. EFFECTS OF CANDESARTAN IN PATIENTS WITH CHRONIC HEART FAILURE AND PRESERVED LEFT-VENTRICULAR EJECTION FRACTION: THE CHARM-PRESERVED TRIAL(2003)
- → Mortality and Morbidity Reduction With Candesartan in Patients With Chronic Heart Failure and Left Ventricular Systolic Dysfunction(2004)394 cited
- → Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program(2006)355 cited